[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597615":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":35,"collaborators":11,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":11,"enrollmentInfo":46,"targetDuration":11,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":11,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"Menzies School of Health Research","OTHER",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Tafenoquine plus DHA-Piperaquine","EXPERIMENTAL",null,[13],"Drug: Tafenoquine plus DHA-Piperaquine",{"label":15,"type":16,"description":11,"interventionNames":11},"DHA-Piperaquine","NO_INTERVENTION",{"label":18,"type":10,"description":11,"interventionNames":19},"Tafenoquine plus artesunate-pyronaridine",[20],"Drug: Tafenoquine plus Artesunate-pyronaridine",[22,26],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Tafenoquine plus DHA-piperaquine",[9],{"type":23,"name":27,"description":27,"armGroupLabels":28,"otherNames":11},"Tafenoquine plus Artesunate-pyronaridine",[18],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Hellen Mnjala","CONTACT","000","hellen.mnjala@menzies.edu.au",{"type":36,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100597615","phase-4-tafenoquine-and-acts-tadore--plus-100597615",false,"NCT07060794","Tafenoquine and ACTs (TADORE- Plus)","TADORE+","Inclusion Criteria:\n\n* P. vivax peripheral parasitaemia (mono-infection)\n* G6PD normal status (G6PD activity ≥70% of the adjusted male median\n* as determined by the Standard G6PD (SD Biosensor, ROK))\n* Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n* Age ≥18 years\n* Haemoglobin at presentation ≥8g\u002Fdl\n* Written informed consent.\n* Living in the study area and willing to be followed for six months\n\nExclusion Criteria:\n\n* Danger signs or symptoms of severe malaria\n* Pregnant or lactating females\n* Regular use of drugs with haemolytic potential\n* Known hypersensitivity to any of the study drugs\n* History of any psychiatric disorder","ALL","18 Years",{"count":47,"type":48},507,"ESTIMATED","INTERVENTIONAL",[51],"PHASE4","A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).",[54],"Vivax Malaria","NOT_YET_RECRUITING","2026-03-16",{"date":58,"type":59},"2026-03-18","ACTUAL",{"date":61,"type":48},"2026-06",{"date":63,"type":48},"2028-06",{"name":5,"class":6}]